ClinicalTrials.gg
CompletedNCT04312594Updated Dec 12, 2024

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of Jaktinib Hydrochloride Tablets and Jaktinib Hydrochloride Tablets in Idiopathic Pulmonary Fibrosis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Enrollment
29th of 60
91 · median 83
Started
2020
with 5 others
Phase 2
21 of 67
7 open now
Registered
10th of 67
by date

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 29th largest by enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2020, is one of 21 in phase 2, and was the 10th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blinded, and placebo-controlled phase II study to evaluate the efficacy and safety of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written signed;at least 50 years of age;no gender limitation.
  2. Diagnosed idiopathic pulmonary fibrosis(see 2018.9 guidance that and ERS and JRS and ALAT publish );
  3. FVC%≥45% normal predicted value;
  4. DLCO≥30% normal predicted value;
  5. / FVC ≥0.7

Exclusion criteria

Exclusion Criteria:

  1. A plan of lung transplant after into group for one year.
  2. In addition of IPF,Other causes cause interstitial lung disease in patients;
  3. Patients with bleeding tendency ( > 2, PT or APTT > 1.5 times normal) or cerebral hemorrhage in the past 1 year;
  4. Have used anticoagulant drugs within 1 month(Except for low molecular weight heparin);
  5. An alcoholic or drug abuser;
  6. Expected survival ≤ one year;
  7. Patients who plan to undergo a operation within study period, such as major operations on chest and abdomen;
  8. Previous use of a JAK inhibitor for more than 10 days or treatment failure;
  9. Suspected allergic to Jaktinib Dihydrochloride Monohydrate , similar drugs (Fedratinib,Ruxolitinib)or their ;
  10. Patients with malignant tumors in the previous 5 years;
  11. Patients with other serious diseases that investigators believe may affect patient safety or compliance;
  12. Any significant clinical or laboratory abnormalities that the investigator considers to affect safety assessment, such as: a. uncontrolled diabetes (13.9 tendency > / L), b. had high blood pressure and antihypertensive drug treatment under two or unable to descend to the ranges (systolic blood pressure \< 160 mmHg, diastolic pressure \< 100 mmHg), c. peripheral neuropathy (NCI - CTC AE v5.0 standard grade 2 or above);
  13. Patients hospitalized for deterioration or acute exacerbation of IPF within 1 month prior to screening;
  14. patients who had not fully recovered from surgery within 1 month prior to screening;
  15. Participate in clinical trials of other new drugs or medical devices within 3 months before screening;
  16. Prednisone > 15mg/ day or equivalent within 1 month prior to screening;
  17. Those who had used pirfenidone, Nintedanib, azathioprine, cyclophosphamide, cyclosporine A or other drugs within 1 month prior to screening;
  18. A history of congestive heart failure, uncontrolled or unstable angina or myocardial infarction, cerebrovascular accident or pulmonary embolism occurred within 6 month prior to screening;
  19. Patients with active TB in the 12 months prior to screening;
  20. Screening patients with arrhythmia requiring treatment, or with >480ms;
  21. At the time of screening, there was evidence of severe impairment of organ function : including and AST > 2.5uln;DBIL and > 2.0 ;Serum creatinine > was 1.5 ULN.
  22. Evidence of active and uncontrolled viral infections such as , (HBsAg positive, hbv-dna positive or ≥10000 copies /ml), (anti-hcv antibody or hcv-rna positive), or bacterial, viral, parasitic or fungal infections requiring treatment with any clinical symptoms;
  23. patients with a history of progressive multifocal leukoencephalopathy in Screening ;
  24. Patients with epilepsy or using antipsychotics(Sleep medicine,for diazepam expect) for treatment of mental illness( schizophrenia,depressed,mania,anxiety,and so on) at the time of screening;
  25. Women who are planning to become pregnant or who are pregnant or breast-feeding and who are unable to use effective throughout the trial period;Male patients who did not use condoms during administration and within 1 month after the last dose;
  26. Subjects who cannot be treated and followed up according to the protocol;
  27. Any subject whom the investigator considers inappropriate for this clinical study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Jaktinib 50mg BID

    Patients receive the dose of Jaktinib Hydrochloride Tablets orally 50mg twice daily (BID) for 24 weeks.

    Drug: Jaktinib Hydrochloride Tablets

  • Experimental
    Jaktinib 75mg BID

    Patients receive the dose of Jaktinib Hydrochloride Tablets orally 75mg twice daily (BID) for 24 weeks.

    Drug: Jaktinib Hydrochloride Tablets

  • Placebo comparator
    Placebo

    Patients receive the dose of placebo orally twice daily (BID) for 24 weeks.

    Drug: Placebo

Interventions

  • Patients were administered Jaktinib taken orally as tablets twice daily

    Also known as: Jaktinib

  • Patients were administered Jaktinib taken orally as tablets twice daily

    Also known as: Jaktinib

  • DrugPlacebo

    Patients were administered Placebo taken orally as tablets twice daily

06

What researchers measure

Primary outcomes

  1. Changes in forced vital capacity (FVC) [ Time Frame: 24 weeks ]

    Changes in FVC from 24 weeks to baseline

    Time frame: 24 weeks

Secondary outcomes

  1. Progression-free time [ Time Frame: the onset of disease or death from any cause ]

    The time from a random date to the onset of disease or death from any cause;

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  2. Non-worsening survival time: [ Time Frame:the time from randomization to the first acute exacerbation ];

    acute aggravation events should meet all the following conditions: (1) acute exacerbation or aggravation of respiratory distress within 1 month;Chest CT showed new bilateral ground glass shadows or pulmonary interstitial fibrosis with pulmonary consolidation;(3) exclude heart failure, fluid retention and infection caused by acute dyspnea

    Time frame: from randomization to one month

  3. K-BILD Scale: absolute value of change from baseline [ Time Frame: 24 weeks ]

    absolute value of change from baseline at 24 weeks

    Time frame: 24 weeks

  4. mMRC Dyspnea scale:absolute value of change from baseline [ Time Frame: 24 weeks ]

    absolute value of change from baseline at 24 weeks

    Time frame: 24 weeks

  5. Survival rate: [ Time Frame: 6 months, 12 months, 24 months ]

    Survival rate

    Time frame: 6 months, 12 months, 24 months

  6. The severity and incidence of all adverse events and adverse reactions[ Time Frame: within 28 days after the signing of the informed consent]

    The severity and incidence of all adverse events and adverse reactions

    Time frame: within 28 days after the signing of the informed consent

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jun 2022, 21 months.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 21 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2020
First posted
Mar 18, 2020
StartActual
Sep 8, 2020
Primary completionActual
Jun 9, 2022
CompletionActual
Jun 9, 2022
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04312594
Responsible party
Sponsor
First posted
Mar 18, 2020
Start date
Sep 8, 2020
Primary completion
Jun 9, 2022
Completion
Jun 9, 2022
Last update
Dec 12, 2024

Study contacts

Jason Wu
study chair · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion